SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

NCT05345327 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

994

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin
DRUG: Metformin

Sponsor

The George Institute

Collaborators

[object Object]
[object Object]
[object Object]